GlaxoSmithKline Net Income From Continuing Ops from 2010 to 2026
| GSK Stock | USD 52.50 0.90 1.74% |
Net Income From Continuing Ops | First Reported 2000-03-31 | Previous Quarter 1.6 B | Current Value 2.1 B | Quarterly Volatility 1.4 B |
Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 B, Interest Expense of 495.6 M or Total Revenue of 19.8 B, as well as many indicators such as Price To Sales Ratio of 1.91, Dividend Yield of 0.0394 or PTB Ratio of 4.39. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
GlaxoSmithKline | Net Income From Continuing Ops | Build AI portfolio with GlaxoSmithKline Stock |
Historical Net Income From Continuing Ops data for GlaxoSmithKline PLC serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether GlaxoSmithKline PLC ADR represents a compelling investment opportunity.
Latest GlaxoSmithKline PLC's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of GlaxoSmithKline PLC ADR over the last few years. It is GlaxoSmithKline PLC's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GlaxoSmithKline PLC's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
GlaxoSmithKline Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 9,103,909,705 | |
| Geometric Mean | 4,679,855,526 | |
| Coefficient Of Variation | 217.87 | |
| Mean Deviation | 9,024,064,739 | |
| Median | 5,096,000,000 | |
| Standard Deviation | 19,834,636,395 | |
| Sample Variance | 393412800.9T | |
| Range | 84.7B | |
| R-Value | (0.17) | |
| Mean Square Error | 407085041.6T | |
| R-Squared | 0.03 | |
| Significance | 0.51 | |
| Slope | (679,405,000) | |
| Total Sum of Squares | 6294604814.7T |
GlaxoSmithKline Net Income From Continuing Ops History
About GlaxoSmithKline PLC Financial Statements
GlaxoSmithKline PLC investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how GlaxoSmithKline Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 2.7 B | 2.5 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of GlaxoSmithKline PLC Correlation against competitors. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. Market participants price GlaxoSmithKline higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive GlaxoSmithKline PLC assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.232 | Dividend Share 0.64 | Earnings Share 3.75 | Revenue Per Share | Quarterly Revenue Growth 0.067 |
Investors evaluate GlaxoSmithKline PLC ADR using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating GlaxoSmithKline PLC's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause GlaxoSmithKline PLC's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, GlaxoSmithKline PLC's market price signifies the transaction level at which participants voluntarily complete trades.